Macrocyclic MCL1 inhibitors for cancer treatment

• 收藏
• 分享

专利权人:

Astrazeneca AB 151 85 Södertälje

发明人:

HIRD, Alexander,BELMONTE, Matthew,YANG, Wenzhan,SECRIST, John,ROBBINS, Daniel,KAZMIRSKI, Steven,WU, Dedong,PENG, Bo,JOHANNES, Jeffrey,LAMB, Michelle,YE, Qing,ZHENG, Xiaolan

申请号：

MA44721

公开号：

MA44721B1

申请日:

2017.04.21

申请国别(地区):

MA

年份:

2020

代理人:

摘要：

The invention relates to a compound, which is 17-chloro-5, 13, 13, 14, 22-tetramethyl-28-oxyoxy- 2, 9-dimethyl-28-oxyoxy- 2, 6, 12, 12, 13, 13, 22-pentaazahepheptyring carboxylic acid [, 27.7.1.14, 7.011, 15.016, 27.7.1.14, 7.011, 15.016, 21.020, 24.030, 35, 35, 37, 37, 37, 37, 4, 38, 16, 6, 11, 11, 14, 16, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, this is a good example.Enantiomers and their pharmaceutically acceptable salts. The invention also relates to 17-chloro- 5, 13, 14, 22-tetramethyl-5, 13, 14, 22-tetramethyl-28-oxa-2, 9-sulfur-5, 6, 12, 12, 13, 22, 22-five nitrogen heteroring [, 27.7.1.14, 7.011, 15.016, 21.020, 24.030, 35] octane-1 ("37.4") ("38, 6, 11, 11, 14, 13, 22, 22-pentanitrogen heteroring [, 27.7.1.14, 7.011.011, 17, 17, 15016, 21.020, 24.030, 35) (" octane "(" 37.4 "(, 38, 38, 6, 6, 6, 6, 6, 6, 6, 6, 38, 6, 6, 38, 6, 6, 6 11, 14, 16, 23, 23, 23-3, 23-3, 23-10-1) And corresponding enantiomers and pharmaceutically acceptable salts, and methods of treating cancer with these compounds and compositions.L'invention concerne un composé qui est l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique (formule 1), des énantiomères et des sels pharmaceutiquement acceptables correspondants. L'invention concerne également des compositions pharmaceutiques de l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique, et des énantiomères et des sels pharmaceutiquement acceptables correspondants, et des méthodes de traitement du cancer avec ces composés et ces compositions.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/